Acute Lymphoblastic Leukemia Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Acute Lymphoblastic Leukemia Therapeutics Market Analysis
One of the major factors responsible for the growth of this market includes the rising occurrence of acute lymphoblastic leukemia (ALL) globally. The number of new cases being recorded each year is around 1.7 per 100,000 men and women per year. It has been estimated by the American Cancer Institute that in 2019, there will be around 5,930 new cases of ALL i.e. 3,280 in males and 2,650 in females. In addition, by 2020, it has been estimated that the number of cases of ALL may range around 0.4 to 2 per 100,000 population in the Asia-Pacific and South American countries.
There is a rise in the number of cases primarily due to the adoption of western lifestyles, including dietary changes and sedentary lifestyles. Moreover, globally, the prevalence is expected to increase during the forecast period, which shall be the major factor for the growth of this market.
Acute Lymphoblastic Leukemia Therapeutics Market Trends
This section covers the major market trends shaping the Acute Lymphoblastic Leukemia Therapeutics Market according to our research experts:
Chemotherapy is Expected to Dominate the Type of Therapy Segment
The American Cancer Association stated that chemotherapy is the main treatment for the people suffering from acute lymphoblastic leukemia (ALL), and it has three phases, such as remission, consolidation, and maintenance. Chemotherapy uses cytotoxic drugs for the destruction of cancer cells.
Amsacrine (NordMedica), cyclophosphamide (Baxter), and cytarabine (Pfizer) are some of the drugs that are used for chemotherapy in ALL. Global pharmaceutical players, such as Baxter International, and Pfizer, are providing these drugs. ALL is the most common cancer in children, adolescents, and young adults younger than 20 years, accounting for 19.8% of all cancer cases in this age group, as per a 2019 report by the Leukemia & Lymphoma Society. Hence, the market for chemotherapy is also expected to boost due to high prevalence of ALL, especially among children.
North America to Dominate the Market Over the Forecast Period
North America is expected to dominate this market, due to the rising number of cases of this disease in the region, owing to genetic factors, environmental factors, and radiation. Moreover, favorable government policies, well-established healthcare infrastructure, and the presence of multinational companies make this region dominant in this market.
Asia-Pacific is also expected to register a high CAGR during the forecast period, owing to several factors, such as high unmet clinical needs, huge patient pool, and the rising awareness about early diagnosis in emerging countries.
Acute Lymphoblastic Leukemia Therapeutics Industry Overview
The market for acute lymphoblastic leukemia is moderately competitive and consists of the big players as well as the mid-sized companies. Owing to the rising focus of most of the pharmaceutical companies on oncology, it is expected that few new small-sized companies will also penetrate the market in the near future.
Acute Lymphoblastic Leukemia Therapeutics Market Leaders
-
Pfizer Inc.
-
Bristol-Myers Squibb Company
-
Novartis AG
-
SymBio Pharmaceuticals Limited
-
Genmab AS
*Disclaimer: Major Players sorted in no particular order
Acute Lymphoblastic Leukemia Therapeutics Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Rise in the Incidences of Acute Lymphoblastic Leukemia
-
4.2.2 Increasing Initiatives Taken by the Government and Private Organizations
-
-
4.3 Market Restraints
-
4.3.1 Stringent Regulatory Pathways
-
4.3.2 High Cost Asscoiated with the Treatment
-
-
4.4 Porter's Five Forces Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Type of Cell
-
5.1.1 B-cell ALL
-
5.1.2 T-cell ALL
-
5.1.3 Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL
-
-
5.2 By Type of Therapy
-
5.2.1 Chemotherapy
-
5.2.1.1 Hyper - CVAD Regimen
-
5.2.1.2 CALGB 8811 Regimen
-
5.2.1.3 Linker Regimen
-
5.2.1.4 Nucleoside Inhibitors
-
5.2.1.5 Other Types of Therapies
-
-
5.2.2 Targeted Therapy
-
5.2.3 Radiation Therapy
-
5.2.4 Stem Cell Transplantation
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
5.3.2 Europe
-
5.3.2.1 Germany
-
5.3.2.2 United Kingdom
-
5.3.2.3 France
-
5.3.2.4 Italy
-
5.3.2.5 Spain
-
5.3.2.6 Rest of Europe
-
-
5.3.3 Asia-Pacific
-
5.3.3.1 China
-
5.3.3.2 Japan
-
5.3.3.3 India
-
5.3.3.4 Australia
-
5.3.3.5 South Korea
-
5.3.3.6 Rest of Asia-Pacific
-
-
5.3.4 Middle East & Africa
-
5.3.4.1 GCC
-
5.3.4.2 South Africa
-
5.3.4.3 Rest of Middle East & Africa
-
-
5.3.5 South America
-
5.3.5.1 Brazil
-
5.3.5.2 Argentina
-
5.3.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Bristol Myer Squibb Company
-
6.1.2 Celegene Corporation
-
6.1.3 Eisai Co Ltd
-
6.1.4 Erytech Pharma
-
6.1.5 F. Hoffmann-La Roche Ltd
-
6.1.6 Genmab A/S
-
6.1.7 GlaxoSmithKline PLC
-
6.1.8 Novartis AG
-
6.1.9 Pfizer Inc.
-
6.1.10 Sanofi SA
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Acute Lymphoblastic Leukemia Therapeutics Industry Segmentation
As per the scope of the report, acute lymphoblastic leukemia (ALL), also called lymphoblastic leukemia, is one of the most common types of cancer, which spreads in the body through lymph nodes, spinal cord, liver, spleen, and central nervous system, among others. B-cell ALL, T-cell ALL, and Philadelphia chromosome-positive ALL (Ph+ ALL) are three of the most common primary types of ALL. B-cell ALL is the most common type. The treatment of patients with Ph+ ALL involves precise drugs that target the gene products.
| By Type of Cell | |
| B-cell ALL | |
| T-cell ALL | |
| Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL |
| By Type of Therapy | |||||||
| |||||||
| Targeted Therapy | |||||||
| Radiation Therapy | |||||||
| Stem Cell Transplantation |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Acute Lymphoblastic Leukemia Therapeutics Market Research FAQs
What is the current Acute Lymphoblastic Leukemia Therapeutics Market size?
The Acute Lymphoblastic Leukemia Therapeutics Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)
Who are the key players in Acute Lymphoblastic Leukemia Therapeutics Market?
Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, SymBio Pharmaceuticals Limited and Genmab AS are the major companies operating in the Acute Lymphoblastic Leukemia Therapeutics Market.
Which is the fastest growing region in Acute Lymphoblastic Leukemia Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Acute Lymphoblastic Leukemia Therapeutics Market?
In 2024, the North America accounts for the largest market share in Acute Lymphoblastic Leukemia Therapeutics Market.
What years does this Acute Lymphoblastic Leukemia Therapeutics Market cover?
The report covers the Acute Lymphoblastic Leukemia Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Acute Lymphoblastic Leukemia Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Acute Lymphocytic Leukemia Therapeutics Industry Report
Statistics for the 2024 Acute Lymphocytic Leukemia Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Acute Lymphocytic Leukemia Therapeutics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
